Search Clinical Trials
Sponsor Condition of Interest |
---|
The Effects of Suvorexant on Sleep, Stress, and Cue-reactivity in Methamphetamine Use Disorder
The University of Texas Health Science Center, Houston
Methamphetamine Use Disorder
The purpose of this study is to determine the effects of SUVO on sleep, stress, and cue
reactivity/craving and to evaluate the preliminary safety and side effects profile of
suvorexant (SUVO)
expand
The purpose of this study is to determine the effects of SUVO on sleep, stress, and cue reactivity/craving and to evaluate the preliminary safety and side effects profile of suvorexant (SUVO) Type: Interventional Start Date: Mar 2023 |
COVID-19 Booster Vaccine in Autoimmune Disease Non-Responders
National Institute of Allergy and Infectious Diseases (NIAID)
Rheumatoid Arthritis (RA)
Systemic Lupus Erythematosus (SLE)
Pemphigus Vulgaris
Multiple Sclerosis (MS)
Systemic Sclerosis (SSc)
This is a randomized, multi-site, adaptive, open-label clinical trial comparing the immune
response to different additional doses of COVID-19 vaccine in participants with autoimmune
disease requiring IS medications. All study participants will have negative serologic or
suboptimal... expand
This is a randomized, multi-site, adaptive, open-label clinical trial comparing the immune response to different additional doses of COVID-19 vaccine in participants with autoimmune disease requiring IS medications. All study participants will have negative serologic or suboptimal responses (defined as a Roche Elecsys® Anti-SARS-CoV-2 S result ≤200 U/mL) or a low immune response (defined as a Roche Elecsys® Anti-SARS-CoV-2 S result >200 U/ml and ≤2500 U/mL) to their previous doses of COVID-19 vaccine. The study will focus on 5 autoimmune diseases in adults: - Systemic Lupus Erythematosus (SLE) - Rheumatoid Arthritis (RA) - Multiple Sclerosis (MS) - Systemic Sclerosis (SSc), and - Pemphigus. This study will focus on 4 autoimmune diseases in pediatric participants: - Systemic Lupus Erythematosus (SLE) - Juvenile Idiopathic Arthritis (JIA) - Pediatric-Onset Multiple Sclerosis (POMS) - Juvenile Dermatomyositis (JDM) Type: Interventional Start Date: Aug 2021 |
Pivotal, Randomized, Open-label Study of Optune® (Tumor Treating Fields) Concomitant With RT & TMZ for...
NovoCure GmbH
Glioblastoma Multiforme
To test the effectiveness and safety of Optune® given concomitantly with radiation therapy
(RT) and temozolomide (TMZ) in newly diagnosed GBM patients, compared to radiation therapy
and temozolomide alone. In both arms, Optune® and maintenance temozolomide are continued
following... expand
To test the effectiveness and safety of Optune® given concomitantly with radiation therapy (RT) and temozolomide (TMZ) in newly diagnosed GBM patients, compared to radiation therapy and temozolomide alone. In both arms, Optune® and maintenance temozolomide are continued following radiation therapy. Type: Interventional Start Date: Dec 2020 |
Embolization of the Middle Meningeal Artery With ONYX™ Liquid Embolic System for Subacute and Chronic...
Medtronic Neurovascular Clinical Affairs
Subdural Hematoma
The purpose of this study is to evaluate the safety and efficacy of embolization of the
middle meningeal artery (MMA) using the Onyx™ Liquid Embolic System (LES) for treatment of
symptomatic subacute or chronic subdural hematoma (SDH)
expand
The purpose of this study is to evaluate the safety and efficacy of embolization of the middle meningeal artery (MMA) using the Onyx™ Liquid Embolic System (LES) for treatment of symptomatic subacute or chronic subdural hematoma (SDH) Type: Interventional Start Date: Oct 2020 |
The Imperative Trial: Treatment of Acute Ischemic Stroke With the Zoom Reperfusion System
Imperative Care, Inc.
Ischemic Stroke
Acute Stroke
The trial is designed to assess the safety and efficacy of using the Zoom Reperfusion System
in subjects diagnosed with acute ischemic stroke and undergoing a thrombectomy procedure
within 8 hours of last known well.
expand
The trial is designed to assess the safety and efficacy of using the Zoom Reperfusion System in subjects diagnosed with acute ischemic stroke and undergoing a thrombectomy procedure within 8 hours of last known well. Type: Interventional Start Date: Oct 2021 |
A Study to Evaluate the Efficacy and Safety of BIIB093 in Participants With Brain Contusion
Biogen
Brain Contusion
The primary objective is to determine if BIIB093 reduces brain contusion expansion by Hour 96
when compared to placebo.
The secondary objectives are to evaluate the effects of BIIB093 on acute neurologic status,
functional outcomes, and treatment requirements, to further... expand
The primary objective is to determine if BIIB093 reduces brain contusion expansion by Hour 96 when compared to placebo. The secondary objectives are to evaluate the effects of BIIB093 on acute neurologic status, functional outcomes, and treatment requirements, to further differentiate the mechanism of action of BIIB093 on contusion expansion by examining differential effects on hematoma and edema expansion, and to determine if BIIB093 improves survival at Day 90 when compared to placebo. Type: Interventional Start Date: Oct 2019 |
Testing Immunotherapy Versus Observation in Patients With HPV Throat Cancer
National Cancer Institute (NCI)
Clinical Stage II HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8
Clinical Stage III HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8
Pathologic Stage II HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8
Pathologic Stage III HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8
This phase III trials studies whether maintenance immunotherapy (nivolumab) following
definitive treatment with radiation and chemotherapy (cisplatin) result in significant
improvement in overall survival (time being alive) and progression-free survival (time being
alive without... expand
This phase III trials studies whether maintenance immunotherapy (nivolumab) following definitive treatment with radiation and chemotherapy (cisplatin) result in significant improvement in overall survival (time being alive) and progression-free survival (time being alive without cancer) for patients with intermediate risk human papillomavirus (HPV) positive oropharynx cancer (throat cancer) that has spread to nearby tissue or lymph nodes. Drugs used in chemotherapy such as cisplatin work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Radiation therapy uses high energy rays to kill tumor cells and shrink tumors. Immunotherapy with monoclonal antibodies, such as nivolumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. It is not yet known whether chemotherapy and radiation therapy followed by maintenance nivolumab therapy works better than chemotherapy and radiation therapy alone in treating patients with HPV positive oropharyngeal cancer. Type: Interventional Start Date: Jun 2019 |
A Study Evaluating the Efficacy and Safety of Ralinepag to Improve Treatment Outcomes in PAH Patients
United Therapeutics
PAH
Pulmonary Hypertension
Pulmonary Arterial Hypertension
Hypertension
Connective Tissue Diseases
Study ROR-PH-301, ADVANCE OUTCOMES, is designed to assess the efficacy and safety of
ralinepag when added to pulmonary arterial hypertension (PAH) standard of care or
PAH-specific background therapy in subjects with World Health Organization (WHO) Group 1 PAH.
expand
Study ROR-PH-301, ADVANCE OUTCOMES, is designed to assess the efficacy and safety of ralinepag when added to pulmonary arterial hypertension (PAH) standard of care or PAH-specific background therapy in subjects with World Health Organization (WHO) Group 1 PAH. Type: Interventional Start Date: Aug 2018 |
Continuous Positive Airway Pressure (CPAP) for Sleep Apnea in Pregnancy
The George Washington University Biostatistics Center
Obstructive Sleep Apnea of Adult
Preeclampsia
Obstetrical Complications
A randomized controlled trial of 1,500 women to assess whether treatment of obstructive sleep
apnea with continuous positive airway pressure (CPAP) in pregnancy will result in a reduction
in the rate of hypertensive disorders of pregnancy.
expand
A randomized controlled trial of 1,500 women to assess whether treatment of obstructive sleep apnea with continuous positive airway pressure (CPAP) in pregnancy will result in a reduction in the rate of hypertensive disorders of pregnancy. Type: Interventional Start Date: Aug 2018 |
MILD® Percutaneous Image-Guided Lumbar Decompression: A Medicare Claims Study
Vertos Medical, Inc.
Lumbar Spinal Stenosis
This prospective longitudinal study will compare incidence rates of Medicare beneficiary
surgical and minimally invasive intervention post index procedure, as well as harms
associated with the MILD procedure, at 24 months post-treatment with MILD, tested against a
control... expand
This prospective longitudinal study will compare incidence rates of Medicare beneficiary surgical and minimally invasive intervention post index procedure, as well as harms associated with the MILD procedure, at 24 months post-treatment with MILD, tested against a control group of similar patients that have had a comparable procedure. This study will start with patients treated with a study procedure having an index date on or after January 1, 2017, and enrollment will continue until stopped by the sponsor. Type: Observational Start Date: Mar 2017 |
EValuating trEatment RESponses of Dupilumab Versus Omalizumab in Type 2 Patients
Sanofi
Chronic Rhinosinusitis With Nasal Polyps
Asthma
Primary Objective
-To evaluate the efficacy of dupilumab compared to omalizumab in reducing the polyp size and
improving sense of smell
Secondary Objectives
- To evaluate the efficacy of dupilumab in improving CRSwNP symptoms at Week 24 compared... expand
Primary Objective -To evaluate the efficacy of dupilumab compared to omalizumab in reducing the polyp size and improving sense of smell Secondary Objectives - To evaluate the efficacy of dupilumab in improving CRSwNP symptoms at Week 24 compared to omalizumab - To evaluate the efficacy of dupilumab in improving lung function at Week 24 compared to omalizumab - To evaluate the efficacy of dupilumab in improving CRSwNP total symptom score (TSS) at Week 24 compared to omalizumab - To evaluate the effect of dupilumab on health related quality of life (HRQoL) at week 24 compared to omalizumab - To evaluate the efficacy of dupilumab in improving nasal peak inspiratory flow at Week 24 compared to omalizumab - To evaluate the effect of dupilumab on CRSwNP overall disease severity at Week 24 compared to omalizumab - To evaluate the effect of dupilumab on asthma control at Week 24 compared to omalizumab - To evaluate the safety of dupilumab and omalizumab Type: Interventional Start Date: Sep 2021 |
An Open-label Extension Trial of HZNP-HZN-825-301 in Adult Participants With Diffuse Cutaneous Systemic...
Horizon Pharma Ireland, Ltd., Dublin Ireland
Diffuse Cutaneous Systemic Sclerosis
Sclerosis, Systemic
Primary Objectives:
1. The primary efficacy objective is to assess the efficacy of 52 weeks of open-label
treatment with HZN-825 in participants with diffuse cutaneous systemic sclerosis, as
measured by change from both baselines in forced vital capacity percent... expand
Primary Objectives: 1. The primary efficacy objective is to assess the efficacy of 52 weeks of open-label treatment with HZN-825 in participants with diffuse cutaneous systemic sclerosis, as measured by change from both baselines in forced vital capacity percent (FVC %) predicted. 2. The primary safety objective is to examine the safety and tolerability of 52 weeks of open-label treatment with HZN-825, inclusive of, but not limited to, adverse events (AEs), serious AEs (SAEs) and the adverse event of special interest (AESI), from Day 1 to 4 weeks after last dose. Type: Interventional Start Date: Nov 2022 |
Study of Tecovirimat for Human Monkeypox Virus
National Institute of Allergy and Infectious Diseases (NIAID)
Monkeypox
A5418 is a randomized, placebo-controlled, double-blind study to establish the efficacy of
tecovirimat for the treatment of people with laboratory-confirmed or presumptive HMPXV
disease.
expand
A5418 is a randomized, placebo-controlled, double-blind study to establish the efficacy of tecovirimat for the treatment of people with laboratory-confirmed or presumptive HMPXV disease. Type: Interventional Start Date: Sep 2022 |
Biomarker and Edema Attenuation in IntraCerebral Hemorrhage (BEACH)
Johns Hopkins University
Intracerebral Hemorrhage
This first-in-patient phase 2a pilot study will assess the safety and tolerability of
MW01-6-189WH (hereafter called MW189) in patients with Intracerebral Hemorrhage (ICH).
expand
This first-in-patient phase 2a pilot study will assess the safety and tolerability of MW01-6-189WH (hereafter called MW189) in patients with Intracerebral Hemorrhage (ICH). Type: Interventional Start Date: Oct 2022 |
Endoscopic Ultrasound PANcreatic CAncer RaDIofrequeNcy AbLation
The University of Texas Health Science Center, Houston
Pancreatic Ductal Adenocarcinoma (PDAC)
The objectives of this study are to determine the feasibility, tolerability, and treatment
effect of Endoscopic Ultrasound (EUS) Radiofrequency ablation (RFA) plus standard-of-care
Neoadjuvant chemotherapy (NAC) in the treatment of Pancreatic Ductal Adenocarcinoma (PDAC).... expand
The objectives of this study are to determine the feasibility, tolerability, and treatment effect of Endoscopic Ultrasound (EUS) Radiofrequency ablation (RFA) plus standard-of-care Neoadjuvant chemotherapy (NAC) in the treatment of Pancreatic Ductal Adenocarcinoma (PDAC). Endoscopic Ultrasound (EUS) Radiofrequency ablation (RFA) and Neoadjuvant chemotherapy (NAC) will be performed before tumor resection surgery, with the goal of shrinking a tumor or stopping the spread of cancer so that surgery might be less invasive and more effective. Type: Interventional Start Date: Jul 2021 |
A Multicenter Trial to Evaluate the Efficacy, Safety, Tolerability and Pharmacokinetics of HZN-825 in...
Horizon Therapeutics Ireland DAC
Diffuse Cutaneous Systemic Sclerosis
Sclerosis, Systemic
This is a randomized, double-blind, placebo-controlled, repeat-dose, multicenter trial.
Participants will be screened within 4 weeks prior to the Baseline (Day 1) Visit.
Approximately 300 participants who meet the trial eligibility criteria will be randomized on
Day 1 in a... expand
This is a randomized, double-blind, placebo-controlled, repeat-dose, multicenter trial. Participants will be screened within 4 weeks prior to the Baseline (Day 1) Visit. Approximately 300 participants who meet the trial eligibility criteria will be randomized on Day 1 in a 1:1:1 ratio to receive HZN-825 300 mg QD, HZN-825 300 mg BID or placebo for 52 weeks. The trial will include up to a 4-week Screening Period and a 52-week Double-blind Treatment Period. Participants will take their first dose of trial drug at the clinic and will return to the clinic for trial visits at Week 4 and every 6 weeks thereafter until Week 52. All participants who complete the Double-blind Treatment Period (Week 52) will be eligible to enter a 52-week extension trial (HZNP-HZN-825-302, NCT05626751). Participants not entering the extension will return to the clinic for a Safety Follow-up Visit 4 weeks after the last dose of trial drug. Type: Interventional Start Date: Apr 2021 |
Brain Oxygen Optimization in Severe TBI, Phase 3
University of Michigan
Brain Injuries, Traumatic
BOOST3 is a randomized clinical trial to determine the comparative effectiveness of two
strategies for monitoring and treating patients with traumatic brain injury (TBI) in the
intensive care unit (ICU). The study will determine the safety and efficacy of a strategy
guided... expand
BOOST3 is a randomized clinical trial to determine the comparative effectiveness of two strategies for monitoring and treating patients with traumatic brain injury (TBI) in the intensive care unit (ICU). The study will determine the safety and efficacy of a strategy guided by treatment goals based on both intracranial pressure (ICP) and brain tissue oxygen (PbtO2) as compared to a strategy guided by treatment goals based on ICP monitoring alone. Both of these alternative strategies are used in standard care. It is unknown if one is more effective than the other. In both strategies the monitoring and goals help doctors adjust treatments including the kinds and doses of medications and the amount of intravenous fluids given, ventilator (breathing machine) settings, need for blood transfusions, and other medical care. The results of this study will help doctors discover if one of these methods is more safe and effective. Type: Interventional Start Date: Aug 2019 |
ACURATE IDE: Safety and Effectiveness Study of ACURATE Valve for Transcatheter Aortic Valve Replacement
Boston Scientific Corporation
Aortic Stenosis
To evaluate safety and effectiveness of the ACURATE Transfemoral Aortic Valve System for
transcatheter aortic valve replacement (TAVR) in subjects with severe native aortic stenosis
who are indicated for TAVR.
expand
To evaluate safety and effectiveness of the ACURATE Transfemoral Aortic Valve System for transcatheter aortic valve replacement (TAVR) in subjects with severe native aortic stenosis who are indicated for TAVR. Type: Interventional Start Date: Jun 2019 |
The LATITUDE Study: Long-Acting Therapy to Improve Treatment SUccess in Daily LifE
National Institute of Allergy and Infectious Diseases (NIAID)
HIV Infections
The purpose of this study is to compare the efficacy, safety, and durability of two different
strategies to treat participants with a history of sub-optimal adherence and control of their
HIV infection: long-acting (LA) antiretroviral therapy (ART) and all-oral standard of care... expand
The purpose of this study is to compare the efficacy, safety, and durability of two different strategies to treat participants with a history of sub-optimal adherence and control of their HIV infection: long-acting (LA) antiretroviral therapy (ART) and all-oral standard of care (SOC). Type: Interventional Start Date: Mar 2019 |
Non-Complex Biliary Stones DSC vs ERC
Boston Scientific Corporation
Biliary Stones
To prospectively compare non-complex biliary stone clearance using fluoroscopy/radiation-free
direct solitary cholangioscopy (DSC) utilizing the SpyGlass™ system with non-complex biliary
stone clearance using standard endoscopic retrograde cholangiography (ERC).
expand
To prospectively compare non-complex biliary stone clearance using fluoroscopy/radiation-free direct solitary cholangioscopy (DSC) utilizing the SpyGlass™ system with non-complex biliary stone clearance using standard endoscopic retrograde cholangiography (ERC). Type: Interventional Start Date: Sep 2018 |
Perioperative Warming Measures in Cesarean Delivery
The University of Texas Health Science Center, Houston
Hypothermia; Anesthesia
Hypothermia, Newborn
Hypothermia, Sequela
The purpose of this study is to evaluate the best method for keeping patients warm during
cesarean deliveries and the effect of temperature change on the patient and baby
expand
The purpose of this study is to evaluate the best method for keeping patients warm during cesarean deliveries and the effect of temperature change on the patient and baby Type: Interventional Start Date: Aug 2021 |
BIO 300 Oral Suspension in Previously Hospitalized Long COVID Patients
Humanetics Corporation
COVID-19
Long COVID
Pulmonary Fibrosis
Post-acute Respiratory Complications of COVID-19
This is a randomized, double-blinded, placebo-controlled, two-arm study to evaluate the
safety and efficacy of BIO 300 Oral Suspension (BIO 300) as a therapy to improve lung
function in patients that were hospitalized for severe COVID-19-related illness and continue
to experience... expand
This is a randomized, double-blinded, placebo-controlled, two-arm study to evaluate the safety and efficacy of BIO 300 Oral Suspension (BIO 300) as a therapy to improve lung function in patients that were hospitalized for severe COVID-19-related illness and continue to experience post-acute respiratory complications associated with Long-COVID after discharge. Patients will be randomized 1:1 to receive BIO 300 or placebo. Type: Interventional Start Date: Nov 2020 |
Nitrous Oxide For Endoscopic Ablation of Refractory Barrett's Esophagus (NO FEAR-BE)
University of North Carolina, Chapel Hill
Barrett Esophagus
Intestinal Metaplasia
Esophageal Dysplasia
A multicenter, prospective, single arm, non randomized clinical trial to evaluate the safety
and efficacy of the C2 CryoBalloon Focal Ablation System (CbFAS) for the treatment of
persistent dysplasia or intestinal metaplasia (IM) in the tubular esophagus after 3 or more
radiofrequency... expand
A multicenter, prospective, single arm, non randomized clinical trial to evaluate the safety and efficacy of the C2 CryoBalloon Focal Ablation System (CbFAS) for the treatment of persistent dysplasia or intestinal metaplasia (IM) in the tubular esophagus after 3 or more radiofrequency ablations (RFA) for dysplastic BE, or <50% eradication of Barrett's Esophagus (BE) after 2 RFA treatments. Type: Interventional Start Date: Sep 2018 |
Maternal-fetal Immune Responses to Fetal Surgery
Mayo Clinic
Spina Bifida
Congenital Diaphragmatic Hernia
Lower Urinary Tract Obstructive Syndrome
Myelomeningocele
Performing surgery in utero on fetuses with certain birth defects has led to significant
improvements in outcomes after birth; however, many of these infants are born preterm which
can decrease the effectiveness of these procedures. The investigators aim to understand the... expand
Performing surgery in utero on fetuses with certain birth defects has led to significant improvements in outcomes after birth; however, many of these infants are born preterm which can decrease the effectiveness of these procedures. The investigators aim to understand the effects of surgery on the maternal and fetal immune system and whether immune activation may be causing some of these infants to be born prematurely. Type: Observational Start Date: Mar 2022 |
FLExAbility Sensor Enabled Substrate Targeted Ablation for the Reduction of VT Study
Abbott Medical Devices
Ventricular Tachycardia
This clinical investigation is intended to demonstrate the safety and effectiveness of
ventricular ablation therapy using the FlexAbility Sensor Enabled Ablation Catheter in
patients with drug-refractory monomorphic ventricular tachycardia in whom ventricular
tachycardia recurs... expand
This clinical investigation is intended to demonstrate the safety and effectiveness of ventricular ablation therapy using the FlexAbility Sensor Enabled Ablation Catheter in patients with drug-refractory monomorphic ventricular tachycardia in whom ventricular tachycardia recurs despite antiarrhythmic drug therapy or when antiarrhythmic drugs are not tolerated or desired. Type: Interventional Start Date: Jun 2018 |
- Previous
- Next